NCT02318056

Brief Summary

Specific Aim 1: To determine if one of three burn dressings provides a less painful healing experience for partial thickness hand. Specific Aim 2: To evaluate if one of three dressings provides greater functionality during and after healing of partial thickness hand burns. Specific Aim 3: To determine if one of three burn dressings promotes aesthetically superior healing results for partial thickness hand burns.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Dec 2015

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 23, 2014

Completed
5 months until next milestone

First Posted

Study publicly available on registry

December 17, 2014

Completed
12 months until next milestone

Study Start

First participant enrolled

December 1, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2016

Completed
Last Updated

July 21, 2016

Status Verified

July 1, 2016

Enrollment Period

7 months

First QC Date

July 23, 2014

Last Update Submit

July 20, 2016

Conditions

Keywords

handburnsthermaldressingAquacel®Mepilex® Transfer AgXeroform®Bacitracin®partial thicknessepithelializationwound healingscarscarring

Outcome Measures

Primary Outcomes (1)

  • pain

    pain as measured by the Patient and Provider Scar Assessment Scale

    baseline to 6 months post-burn injury

Secondary Outcomes (6)

  • pain

    baseline to 6 months post-burn injury

  • pain

    baseline to 6 months post-burn injury

  • functionality

    baseline to 6 months post-burn injury

  • functionality

    baseline to 6 months post-burn injury

  • aesthetic appearance

    baseline to 6 months post-burn injury

  • +1 more secondary outcomes

Other Outcomes (2)

  • quality of life

    baseline to 6 months post-burn injury

  • resilience

    baseline to 6 months post-burn injury

Study Arms (3)

Aquacel® Ag Burn Glove

EXPERIMENTAL

Application of Aquacel® Ag Burn Glove burn dressing

Other: Aquacel® Ag Burn Glove

Mepilex® Transfer Ag

ACTIVE COMPARATOR

Application of Mepilex® Transfer Ag burn dressing

Other: Mepilex® Transfer Ag

Xeroform®/Bacitracin®

ACTIVE COMPARATOR

Application of Xeroform® burn dressing and Bacitracin® topical antibiotic

Drug: antibiotic

Interventions

burn dressing

Also known as: ConvaTec
Aquacel® Ag Burn Glove

burn dressing

Also known as: Safetac®, Molnlycke® Health Care
Mepilex® Transfer Ag

antibiotic burn dressing

Also known as: Bacitracin®, Xeroform®
Xeroform®/Bacitracin®

Eligibility Criteria

Age8 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Patients presenting at Memorial Medical or Southern Illinois University (SIU) Health Care
  • Patients with partial-thickness burn injuries to the dorsum and/or palm of the hand/s that exceeds ½% total body surface area (TBSA) for at least one hand.
  • \< 10% TBSA 2nd and 3rd degree burn injuries
  • Initial clinical presentation \< 5 days post burn injury

You may not qualify if:

  • \< ½ % TBSA involving the hand
  • \> 10%TBSA burn injuries
  • \> 60 years of age
  • \< 8 years of age
  • Patients (or parents of minors) without cognitive capacity to comprehend informed consent
  • Presentation \> 5 days post-burn injury event
  • Pregnant women
  • Full thickness/3rd degree burns to the dorsal and/or palmer hand/s
  • Exposed vital structures (tendons, nerves, bone, vessels)
  • Uncontrolled Type II Diabetes
  • Type I Diabetes
  • History of Chronic Obstructive Pulmonary Disease
  • Have a known allergy to silver products
  • Signs of infection on initial clinical presentation (presence of purulent drainage, significant cellulitis, and/or fever)
  • Smoke/inhalation injuries requiring ventilation
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Southern Illinois University School of Medicine

Springfield, Illinois, 62794-9640, United States

Location

Related Publications (7)

  • Wasiak J, Cleland H, Campbell F. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD002106. doi: 10.1002/14651858.CD002106.pub3.

    PMID: 18843629BACKGROUND
  • Robson MC, Smith DJ Jr, VanderZee AJ, Roberts L. Making the burned hand functional. Clin Plast Surg. 1992 Jul;19(3):663-71.

    PMID: 1633673BACKGROUND
  • Kamolz LP, Kitzinger HB, Karle B, Frey M. The treatment of hand burns. Burns. 2009 May;35(3):327-37. doi: 10.1016/j.burns.2008.08.004. Epub 2008 Oct 25.

    PMID: 18952379BACKGROUND
  • Walburn J, Vedhara K, Hankins M, Rixon L, Weinman J. Psychological stress and wound healing in humans: a systematic review and meta-analysis. J Psychosom Res. 2009 Sep;67(3):253-71. doi: 10.1016/j.jpsychores.2009.04.002. Epub 2009 Jul 2.

    PMID: 19686881BACKGROUND
  • Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: review of the literature. Burns. 2007 Mar;33(2):139-48. doi: 10.1016/j.burns.2006.06.010. Epub 2006 Nov 29.

    PMID: 17137719BACKGROUND
  • Hollinger MA. Toxicological aspects of topical silver pharmaceuticals. Crit Rev Toxicol. 1996 May;26(3):255-60. doi: 10.3109/10408449609012524.

    PMID: 8726163BACKGROUND
  • Bowler PG, Jones SA, Walker M, Parsons D. Microbicidal properties of a silver-containing hydrofiber dressing against a variety of burn wound pathogens. J Burn Care Rehabil. 2004 Mar-Apr;25(2):192-6. doi: 10.1097/01.bcr.0000112331.72232.1b.

    PMID: 15091147BACKGROUND

Related Links

MeSH Terms

Conditions

BurnsCicatrix

Interventions

Anti-Bacterial AgentsBacitracin2,4,6-tribromophenol

Condition Hierarchy (Ancestors)

Wounds and InjuriesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Anti-Infective AgentsTherapeutic UsesPharmacologic ActionsChemical Actions and UsesPeptides, CyclicMacrocyclic CompoundsPolycyclic CompoundsPeptidesAmino Acids, Peptides, and Proteins

Study Officials

  • Nada N Berry, MD

    Southern Illinois University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 23, 2014

First Posted

December 17, 2014

Study Start

December 1, 2015

Primary Completion

July 1, 2016

Study Completion

July 1, 2016

Last Updated

July 21, 2016

Record last verified: 2016-07

Data Sharing

IPD Sharing
Will not share

Locations